Abstract The interactive effects of HIV-1 infection and methamphetamine (METH) abuse in producing cognitive dysfunction represent a serious medical problem; however, the neural mechanisms underlying this interactive neurotoxicity remain elusive. In this study, we report that a combination of low, sub-toxic doses of METH + HIV-1 Tat 1-86 B, but not METH + HIV-1 gp120, directly induces death of rodent midbrain neurons in vitro. The effects of D1-and NMDA-receptor specific antagonists (SCH23390 and MK-801, respectively) on the neurotoxicity of different doses of METH or HIV-1 Tat alone and on the METH + HIV-1Tat interaction in midbrain neuronal cultures suggest that the induction of the cell death cascade by METH and Tat requires both dopaminergic (D1) and N-methyl D-aspartate (NMDA) receptor-mediated signaling. This interactive METH+Tat neurotoxicity does not occur in cultures of hippocampal neurons, which are predominately glutamatergic, express very low levels of dopamine receptors, and have no functional dopamine transporter (DAT). Thus, the presence of a subpopulation of neurons capable of dopamine release/uptake is essential for METH+Tat induction of the cell death cascade. Overall, our results support the hypothesis that METH and HIV-1 Tat disrupt the normal conjunction of signaling between D1 and NMDA receptors, resulting in neural dysfunction and death.
Introduction
Consequences of methamphetamine (METH) use and HIV-1 infection are major public health problems in the world today (Reiner et al. 2009; Bao et al. 2010; Marshall and Werb 2010) . Clinical studies indicate that HIV-1 infection (Grant 2008) and METH dependence (Gouzoulis-Mayfrank and Daumann 2009; Scott et al. 2007 ) are associated with neuropsychological deficits, suggesting that these factors in combination may produce additive or even synergistic adverse effects on neural function (Langford et al. 2003) . While potential mechanisms of adverse independent effects of METH abuse or HIV-1 infection on neuronal functioning have been the subject of many experimental reports (Cadet and Krasnova 2007; Cadet and Krasnova 2009) , fewer studies have been reported on the combined effects of METH and HIV-1 in the brain (Ferris et al. 2008; Rippeth et al. 2004) . This cooperation between HIV-1 and METH may reflect common pathways to neural injury involving both cytotoxic and apoptotic mechanisms (Purohit et al. 2011) .
Indeed, the attempt to integrate recent findings on the individual effects of METH or HIV to gain insight into potential converging pathways of their co-morbid effects on the brain has produced a fairly complex picture of METH+HIV-1 cooperation (Reiner et al. 2009 ). The major emphasis related to the co-morbid effect of METH and HIV-1 in the central nervous system (CNS) has been on the concurrent toxicity of METH and HIV-1 viral proteins (Cadet and Krasnova 2007) . In particular, recent studies have focused on interactions between METH and either the HIV-1Tat protein, the key transactivating regulatory protein (Langford et al. 2004) or on HIV-1 gp120, a viral envelope glycoprotein (Banerjee et al. 2010; Bennett et al. 1995; Roberts et al. 2010) .
In the brain, a primary action of METH is to elevate the levels of extracellular dopamine (DA) by redistribution of DA from synaptic vesicles (via vesicular monoamine transporter, VMAT2) to the neuronal cytoplasm and the reverse transport through the plasma membrane (via the membrane dopamine transporter, DAT) into the extracellular space (Raiteri et al. 1979; Riddle et al. 2006) . Interestingly, our laboratory has found that HIV-1 Tat protein also influences DAT controlled uptake/release of dopamine, thereby producing alterations in functioning of the dopaminergic transmission system (Wallace et al. 2006; Ferris et al. 2009a; Zhu et al. 2009; Zhu et al. 2011 ) and synergistic Tat+cocaine interactions Ferris et al. 2009b; Ferris et al. 2010 ). Thus, interactions between METH and Tat may also involve dopaminergic alterations (Ferris et al. 2008) .
Although the understanding of these mechanisms remains incomplete, the involvement of aberrant glutamate transmission, mitochondrial disruption and the subsequent increased production of free radical species is evident (Riddle et al. 2006) in studies of METH neurotoxicity and in combined Tat+METH toxicity (Flora et al. 2003) . Glutamate signaling may be an important component of METH-induced DAergic deficits. High doses of METH were shown to acutely activate the nigrostriatal pathway to increase glutamate release and mediate long-term DA toxicity in the striatum (Mark et al. 2004) . Antagonists of NMDA receptors, such as MK-801 (dizocilpine) were reported to block METH neurotoxicity in mice by mechanisms independent from thermoregulation (Bowyer et al. 2001 ). The HIV-1 viral proteins Tat and gp120 also interact with the glutamate system, producing excitotoxic neural effects (Shin et al. 2011; Xu et al. 2011; Li et al. 2008) . In sum, interactions between METH and Tat have also been found to involve glutamate signaling in producing neurotoxicity, in addition to dopaminergic interactions.
We hypothesized that the adverse effects of METH and HIV-1 proteins on dopaminergic and glutamatergic neurotransmission may converge/interact via a common substrate, leading to facilitated neurodegeneration. In the present study, two assessments were made: 1) the potential for low, individually non-cytotoxic, doses of METH, HIV-1 Tat or gp120 to produce cell death in combination, and 2) the involvement of D1 and NMDA receptors in combined METH + HIV-1 protein neurotoxicity. Our results suggest that interactions between dopamine and glutamate systems play a key role in the neurotoxicity associated with METH use in HIV-1 positive populations.
Materials and methods
Primary midbrain and hippocampal cell cultures were prepared from 18-day-old Sprague-Dawley rat fetuses as previously described 2008; Aksenova et al. 2006; . In brief, both the midbrain and hippocampal regions were rapidly microdissected and incubated for 15 min in a solution of 2 mg/ml trypsin in Ca2+-and Mg2+-free Hanks' balanced salt solution (HBSS) buffered with 10 mM HEPES (Invitrogen, Carlsbad, CA). Cells were dissociated by trituration and distributed to poly-L-lysine coated culture plates wells containing DMEM/F12 medium (Invitrogen) supplemented with 100 mL/L fetal bovine serum (Sigma Chemicals, St. Louis, MO). After a 24 h period, the DMEM/F12 medium was replaced with 2 %v/v B-27 Neurobasal medium supplemented with 2 mM GlutaMAX and 0.5 % w/v D-(+) glucose (Invitrogen), which was continued throughout the experiment. All experiments were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of South Carolina.
Cultures were used for experiments at 14-21 days in vitro (DIV) and were >90 % neuronal as determined by anti-MAP-2/anti-GFAP/Hoechst fluorescent staining. Cell populations in primary rat fetal brain cultures were further characterized with standard immunocytochemical techniques ) using the antibodies as detailed in Table 1 for the current study. For all immunocytochemistry experiments, cultures were fixed in 4 % paraformaldehyde for 10 min and washed with D-PBS 3 x 5 min. Following fixation, the cultures were treated with 10 % normal horse serum and processed with the appropriate primary antibodies (Table 1) . Primary antibodies were incubated overnight at 4°C. Cells were incubated with secondary antibodies for 1 h at room temperature and then washed 3 x PBS. The presence of microglia in the cultures was assessed using DyLight 594 labeled Tomato lectin (DL-1177, Vector Laboratories, Burlingame, CA). Hoechst was used as a general counterstain to identify cell nuclei in culture.
Treatments of primary rat fetal neuronal cell cultures with METH, Tat, and gp120 was carried out by addition of freshly-prepared stock solutions (separately or in combination) or vehicle (control) into the cell culture growth medium. Recombinant Tat 1-86 B (LAI/Bru strain of HIV-1 clade B, GenBank accession no. K02013) was purchased from Diatheva (Italy). Recombinant full length gp120 LAV (T-tropic) was purchased from Protein Sciences (Meriden, CT). Methamphetamine was obtained from Sigma Chemicals (St. Louis, MO). A range of METH concentrations from 1 μM to 5 mM were used to determine the threshold for drug cytotoxicity in primary cultures of rat fetal neurons. Non-cytotoxic doses of Tat (10 nM) and gp120 (30 pM) were selected based on numerous previous studies using primary CNS cultures (Turchan et al. 2001; Aksenova et al. 2006 Aksenova et al. , 2009 .
Neuronal cell viability was assessed using a microplate reader formatted (Aksenov et al. , 2008 Aksenova et al. 2006 Aksenova et al. , 2009 Adams et al. 2010 ) variant of the Live/Dead assay (Molecular Probes, Inc., Eugene, OR). In brief, the cleavage product of calcein AM produces a green fluorescence (F 530 nm ) when exposed to 494-nm light and is used to identify live cells. Bound ethidium homodimer-1 produces a red fluorescence (F 645 nm ) when exposed to 528-nm light, allowing the identification of dead cells. Fluorescence was measured using a Bio-Tek Synergy HT microplate reader (Bio-Tek Instruments, Inc., Winooski, VT). For each individual cell culture (well), ratios between corrected green and red fluorescence (F 530 nm /F 645 nm , Live/ Dead ratios) were calculated. All individual relative numbers of live and dead cells were expressed in terms of percentages of average maximum Live/Dead ratio determined for the set of non-treated control cell cultures (8-16 wells) from the same plate: [F 530 nm /F 645 nm ] well n /[F 530 nm /F 645 nm ] average max × 100 %. All Live/Dead assays were conducted 72 h after initiating the cell culture treatments.
The co-localization of D1R and NMDAR in cultured rat fetal midbrain neurons was analyzed in midbrain cultures prepared in 24-well plates. Cultured neurons were fixed in 4 % paraformaldehyde, and analyzed using immunofluorescent double-labeling with anti-D1R and anti-NR1 antibodies. A mouse monoclonal antibody generated against the D1 A dopamine receptor (MAB5290, Chemicon, Temecula, CA; 1:200) was used to immunolabel D1R. NMDAR immunolabeling was performed as previously described ), using a rabbit monoclonal primary antibody specific for the NR1 subunit (AB1516, Chemicon, Temecula, CA; 1:500). Secondary antibodies were AlexaFluor Dye-conjugated IgGs (goat anti-rabbit AlexaFluor 488 (green) or anti-mouse Alexa Fluor 594 (red) Molecular Probes, Inc; Eugene OR) against the particular host animal (rabbit or mouse; 1:500). To assess the specificity of fluorescent signals in doublelabeling experiments, one or both of the specific primary antibodies were excluded from the labeling procedure. Images were acquired via a CCD digital camera connected to the Nikon Eclipse 2000 inverted fluorescent microscope under 20X objective magnification and processed with NIS Elements (Nikon) software package. Assessment of cell populations (percentage of single vs. double labeling) was conducted using 3 captured images/well. The specificity of the anti-D1R and anti-NR1 primary antibodies were confirmed (using Western blots of both adult rat brain tissue extracts and cell culture extracts) prior to experimentation.
The involvement of D1 and/or NMDA receptors in METH or METH/HIV-1 protein neurotoxicity was tested using varying concentrations of D1R-specific (SCH23390) and NMDAR-specific (MK-801) antagonists. SCH 23390 and MK 801 were obtained from Sigma Chemicals (St. Louis, MO).
Statistical comparisons were made using ANOVA and planned comparisons were used to determine specific treatment effects. Significant differences were set at P<0.05. The time course of Tat and Tat + METH cell viability curves were best fit with four-parameter sigmoid equations (R 2 >0.99) using SigmaPlot 8.0 software package (Systat Software, Inc., San Jose, CA).
Results
METH cytotoxicity and the effect of concurrent exposure of primary rat fetal midbrain cell cultures to individually noncytotoxic doses of METH and HIV-1 proteins (Tat or gp120) Midbrain primary cell cultures (14-21 DIV) were composed of 90-95 % neurons, 5 %-10 % astrocytes, (determined by anti-MAP2/anti-GFAP immunolabeling) and no microglia (as determined by DyLight 594 labeled tomato lectin). The midbrain neuronal population included tyrosine hydroxylase (TH)-positive (≈52 %), DAT-positive (22-25 %), and D1R-positive (≈84 %) cells.
The Live/Dead cell viability assay was carried out in midbrain cell cultures subjected to varying doses of METH (Fig.1) . No statistically significant change in the viability of rat fetal midbrain neurons was detected when METH concentrations in the growth medium were less than 1 mM. However, the maximum METH dose (5 mM) resulted in a pronounced (≈50 %) decrease in neuronal viability 72 h after treatment.
The combination of 20 μM METH+10 nM Tat produced a statistically significant (P<0.05) decrease (≈20 %) in cell viability after 72 h of the exposure (Fig. 2a) . In contrast, the treatment of midbrain cultures for 72 h with the combination of 20 μM METH+30 pM gp120 did not affect cell viability (Fig. 2b) .
The time course of combined Tat + METH cytotoxicity in midbrain cell cultures Consistent with our previous results Aksenova et al. 2009 ), the Live/Dead ratio in midbrain cultures treated for 72 h with 50 nM Tat 1-86 B was 71.3±2.4 % of control (P<0.05), which approximates the cell viability decrease produced by combination of individually non-cytotoxic doses of Tat and METH. The Live/ Dead ratios measured after 72-h treatment of midbrain cells with the combination of 10 nM Tat +20 μM METH and 10 nM Tat +100 μM METH were 79.4±2.2 % and 72.3±1.8 % of control, respectively (Fig. 3a) . The difference between the decrease in Live/Dead ratios induced by 72 h-long exposure of midbrain cells to either 10 nM Tat in combination with two different individually non-toxic doses of METH or by 50 nM Tat alone was not statistically significant (P>0.05). The time course for cell viability declines in midbrain cell cultures treated by either the combination of individually non-toxic doses of Tat and METH (10 nM Tat +20 μM METH) (Fig. 3b) was similar to that previously reported for 50 nM Tat alone ).
The effect of METH and Tat + METH combinations on the cell viability in hippocampal cell cultures To determine whether METH could potentiate Tat neurotoxicity in a hippocampal primary cell culture predominantly composed of glutamatergic neurons (Mattson 1988 ), we exposed 14-21 DIV-old hippocampal cell culture to METH (20 and 100 μM). The 10 nM Tat 1-86 B, 20 or 100 μM METH alone were not cytotoxic in this cell culture model. As shown in Fig. 6 , neither the 20 μM METH+10 nM Tat, nor the 100 μM METH + 10 nM Tat produced any significant alterations in cell viability in hippocampal cell cultures (Fig. 4) .
Immunolocalization of NMDAR and D1R in midbrain cell cultures NR1 and D1R immunoreactivities overlap in a subset (≈30 %) of primary midbrain neurons (Fig. 5) . Co-localization of NMDARs and D1Rs was observed in both the cell body and in the neuronal processes of midbrain cells (14-21 DIV).
The effect of D1-selective antagonist, SCH 23390, on METH and Tat-induced cytotoxicity in midbrain cell cultures Exposure of 10 μM of SCH23390 (72 h) to midbrain cells was not toxic (Live/Dead ratio0100±1.3 % of control). Cell cultures treated with 10 nM Tat + SCH23390 or with 20 μM METH + SCH23390 failed to exhibit any statistically significant changes in the Live/Dead ratios compared to control (99.4 ± 1.2 % or 98.7 ± 1.5 %, P > 0.05). The 10 μM dose of SCH23390 inhibited (P<0.05) the decrease of Live/Dead ratios in cultures exposed to 10 nM Tat +20 μM METH (Fig. 6 ).
The effect of NMDAR-specific blocker, MK 801, on METH and Tat-induced cytotoxicity in midbrain cell cultures The expression of NMDAR subunits (NR1, NR2A, NR2B) was previously determined in midbrain cell culture lysates ). Different (0.1, 1 and 10 μM) concentrations of MK801 alone or in combination with 10 nM Tat 1-86 B did not produce changes in midbrain cell viability following 72 h of exposure. Co-treatment of cultures with 0.1 or 1 μM MK 801 and 20 μM METH also did not affect the viability of midbrain neurons. However, the combination of 10 μM MK801 with 20 μM METH produced a statistically significant (P<0.05) decrease in Live/Dead ratios. The 0.1 and 1 μM doses of MK801 ameliorated the combined toxicity of 10 nM Tat + 20 μM METH (Fig. 7 ).
Discussion
The current study found that the neurotoxic effects produced by combined (sub-lethal) concentrations of Tat changes in D1R-and NMDAR-dependent signaling. Moreover, the sub-lethal concentration (30 pM) of gp120, did not synergize with METH in our predominantly neuronal midbrain cell cultures (containing <10 % astrocytes and few microglia). The inability to observe direct gp120/METH combined cytotoxicity in a relatively pure neuronal rat fetal midbrain cell culture is consistent with the known importance of glial cells in producing gp120-induced neuronal apoptosis (Lipton 1994a, b) . The cellular pathways to neuronal degeneration mediated by these two viral proteins have common steps, but are not identical. Gp120 has been shown to act primarily via binding to cytokine receptors, particularly, CXCR4, and its ability to cause neuronal death strongly depends on non-neuronal (astrocytic or microglial) cell responses (Meucci and Miller 1996; Dong and Xiong 2006) .
Moreover, we found that low doses of METH were unable to enhance the effects of low dose of Tat in hippocampal cell cultures. The neuronal population in primary hippocampal cell cultures is predominantly glutamatergic (Mattson 1988 ). As such, primary hippocampal neurons exhibit very low levels of D1R-and DAT-specific ligand binding compared to primary midbrain neurons. At 14-21 DIV, 85-90 % of total cell population in rat fetal hippocampal cultures is composed of large pyramidal neurons (Bertrand et al. 2010) . Hippocampal cultures are characterized by very low D1R-specific ligand binding (5±1 fmol/mg protein of [ 3 H]SCH23390 (Silvers et al. 2007) ). In contrast, the specific binding of [ 3 H] SCH23390 was previously determined to be 82.6± 5 fmol/mg protein in our 14-day old midbrain cell cultures (Silvers et al. 2007) . Thus, the current findings in hippocampal cell cultures indicate that the presence of glutamate signaling and a functional DA-dependent signaling system are necessary for the ability of sub-lethal doses of Tat and METH to cooperatively activate the cell death cascade.
The neurotoxic effects resulting from METH-induced changes in the DA uptake/release can be modulated by selective DA receptor ligands (Riddle et al. 2006) . We previously reported that in rat fetal midbrain cultureswhere the majority of neurons expresses DA receptors and a significant portion of the neuronal population possess fully-functional DAT protein -a 10 μM dose of SCH23390 prevented cell death induced by Tat 1-86 B (Silvers et al. 2007) . Although Tat protein is not known to interact directly with D1R, Tat may influence DA receptor activities via direct inhibition of the DAT protein in vitro (Zhu et al. 2009; and in vivo (Ferris et al. 2009a, b) , thereby altering synaptic DA concentrations (Ferris et al. 2010) . Studies in primary cultures containing DAergic neurons suggested the existence of neuronal subsets selectively sensitive to neurodegeneration induced by Tat or METH (Larsen et al. 2002) .
Additionally, studies have suggested that METH can influence the functioning of the glutamatergic transmission system (Yamamoto et al. 1999; Mark et al. 2007; Simões et al. 2007; Swant et al. 2010) . However, it is unclear exactly how METH alters glutamatergic transmission (Swant et al. 2010) . The generally understood mechanism of METH action in the brain is linked to its ability to reverse the carrier-mediated dopamine (DA) uptake system (Raiteri et al. 1979) . High doses of the drug can cause the selective damage and death of DA neurons via oxidative stress-mediated apoptosis (Larsen et al. 2002; Riddle et al. 2006 ). The free radical-mediated demise of DA neurons in vitro, in various CNS cell culture models, is typically observed at millimolar METH concentrations (Choi et al. 2002; Larsen et al. 2002; Jiménez et al. 2004; Kanthasamy et al. 2006; Kanthasamy et al. 2011) . Indeed, we also found a significant decrease in cell viability occurred in midbrain neuronal cell cultures exposed to 1 mM or higher concentrations of METH; however, we found interactive toxicity with Tat at much lower METH doses. Direct interactions of the Tat cysteine-rich domain with the NMDAR (Song et al. 2003; Li et al. 2008 ) results in abnormal activation of the receptor complex and may lead to apoptotic death of Tat-affected neurons ). The NR1 subunit of the NMDA receptor complex (which co-localized with D1R in the current study) is thought to play a critical role in D1R interactions with NMDA receptors (Jocoy et al. 2011) ; D1-NR1 physical interaction occurs via a direct protein-protein interaction mediated by the carboxyl tail of both receptors (Pei et al. 2004) .
Most studies that have investigated cooperative cytotoxicity of METH and HIV-1 proteins have been conducted using CNS cell cultures (Langford et al. 2004; Cadet and Krasnova 2007; Cai and Cadet 2008; Nath et al. 2002) . In contrast, fewer studies of METH + Tat/gp120 toxicity have been conducted in vivo. In a series of animal studies, stereotaxic microinjections of Tat and gp120 into the rat brain were accompanied by the exposure of animals to METH Theodore et al. 2006; Banerjee et al. 2010) , producing neurotoxicity. Using transgenic animal models of HIV-1 protein expression, METH has been demonstrated to have neurotoxic properties and alter behavioral endpoints (Kass et al. 2010; Liu et al. 2009; Silverstein et al. 2011) . Recent studies from our lab, suggest that METH can exacerbate behavioral deficits in HIV-1 transgenic animals (Moran et al. 2012) . Specifically, we found prominent behavioral and neurochemical changes in the adolescent HIV-1 Tg rat, especially consequent to METH challenge. HIV-1 Tg animals that received METH displayed higher MAO-A protein expression and lower TH protein expression relative to control animals. Thus, expression of HIV-1 proteins in animals had significant effects on behavioral and neurochemical measures reflecting integrity of the DA system, and these alterations were especially evident consequent to in vivo METH challenge. These findings suggest that HIV-1 protein + METH interactions may occur in chronic exposure models. Long-term effects of HIV-1 Tat on D1 and NMDA receptor signaling might be anticipated to have a powerful influence on neuroadaptations and learning (Castner and Williams 2007) ; however, interactions between the D1R and NMDAR have yet to be examined in METH-treated HIV-1 transgenic animals.
The 20 μM concentration of METH that was used for the majority of experiments in this study was beneath threshold for inducing death of primary DA neurons (Larsen et al. 2002) and corresponds with the drug concentration limits reported in the study of unsupervised recreational METH users (Melega et al. 2007 ). Additionally, concentrations of Tat that do not induce cell death are comparable with reported circulating concentrations of these viral proteins in the blood of HIV-infected individuals -soluble Tat levels in HIV-1+ patients CSF and plasma have been reported as up to 40 ng/ml (Westendorp et al.; Xiao et al. 2000) . These low Tat levels may be sufficient to activate NMDARs (Bennett et al. 1995; Self et al. 2009 ) thereby altering the release/uptake of catecholamines, particularly, DA (Wallace et al. 2006 ) and interact with METH to produce localized neurotoxicity.
In the present study, we found that approximately 30 % of our cultured midbrain neurons were immunolabeled for both D1 and NR1. D1 and NMDAR are known to co-localize extensively at synaptic, parasynaptic, and nonsynaptic sites in dendritic spines and shafts (Pickel et al. 2006) . Direct physical interactions between D1 and NMDA receptors have been reported (Zhang et al. 2009; Nai et al. 2010; Pei et al. 2004 ). The existence of close interactions between D1R and NMDAR (Missale et al. 2010; Zorumski and Izumi 2012) indicates that alterations in control of DA uptake/release concurrently by METH and Tat may converge with the pathway of HIV protein-mediated NMDAR hyperactivation and, thereby, make D1R/NMDAR-expressing midbrain neurons a highly sensitive target for combined HIV-1 Tat+METH neurotoxicity. Moreover, given that NMDAR activation is key in regulating the number of D1 receptors present in dendritic spines (Scott et al. 2006) , and that maintaining synaptic integrity is critical in preventing HIV-1 neurotoxicity (Bellizzi et al. 2006; Gelman et al. 2012; Ellis et al. 2007) , the D1/NMDA complex may represent a novel target for HIV-1 neurotherapeutics.
In sum, we suggest that the conjunction of signaling between D1 and NMDA receptors contributes to HIV-1 Tat neurotoxicity in midbrain cell cultures that include significant numbers of D1/NR1-expressing neurons. Further investigation of altered D1R-NMDAR interactions in concurrent METH/HIV-1 neurotoxicity may help to understand the neural basis of cognitive deficits produced by HIV-1 and drugs of abuse such as methamphetamine.
